Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48934 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL2631528 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL29763579 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL9164082 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL25410263 | 0.82 | LMNA (0.49) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL6361845 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL7532390 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL11200266 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL2518227 | 0.81 | GAA (0.71) | SMN1; SMN2MEN1KMT2AKDM4ENTRK1 | |
| SCHEMBL12983862 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2APOLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | SMN1; SMN2 2454/4885MEN1 3363/4885KMT2A 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.